SPARC Monoclonal antibody, PBS Only
SPARC Monoclonal Antibody for WB, IHC, IF/ICC, Indirect ELISA
Host / Isotype
Mouse / IgG2a
Reactivity
human
Applications
WB, IHC, IF/ICC, Indirect ELISA
Conjugate
Unconjugated
CloneNo.
1A2C1
Cat no : 66426-1-PBS
Synonyms
Validation Data Gallery
Tested Applications
Recommended dilution
Application | Dilution |
---|---|
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. |
Product Information
66426-1-PBS targets SPARC in WB, IHC, IF/ICC, Indirect ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Mouse / IgG2a |
Class | Monoclonal |
Type | Antibody |
Immunogen | SPARC fusion protein Ag7390 相同性解析による交差性が予測される生物種 |
Full Name | secreted protein, acidic, cysteine-rich (osteonectin) |
Calculated molecular weight | 35 kDa |
Observed molecular weight | 38 kDa, 52 kDa |
GenBank accession number | BC004974 |
Gene symbol | SPARC |
Gene ID (NCBI) | 6678 |
RRID | AB_2881797 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
Storage Buffer | PBS Only |
Storage Conditions | Store at -80°C. |
Background Information
SPARC, also known as ON (Osteonectin) or BM-40 (Basement-membrane protein 40), is an extracellular glycoprotein with the calculated molecular mass of 35 kDa and the apparent molecular mass of 40-43 kDa and 50 kDa (PMID: 7495300, 12365801). SPARC belongs to a group of matricellular proteins defined as secreted components that do not contribute directly to the formation of structural elements but serve to modulate cell-matrix interactions and cellular functions (PMID: 7542656; 12231357). SPARC is expressed at high levels in bone tissue, is distributed widely in many other tissues and cell types, and is associated generally with tissues undergoing morphogenesis, remodeling and wound repair (PMID: 10567433). It elicits changes in cell shape, inhibits cell-cycle progression, and influences the synthesis of extracellular matrix (PMID: 12721366). Altered expression of SPARC has been reported in a variety of cancers, which include breast, ovarian, colorectal, and pancreatic cancer as well as melanoma and glioblastomas (PMID: 18849185).